Pharmacy Lawsuits: Opioid Settlements, DOJ Cases, and FTC Action

Pharmacy lawsuits over the past several years have targeted the country’s largest drugstore chains, grocery pharmacies, pharmacy benefit managers, and independent operators on multiple fronts at once: opioid dispensing, false billing of Medicare and Medicaid, insulin price manipulation, patient data breaches, and individual prescription errors. The aggregate exposure runs into tens of billions of dollars. Opioid-related settlements across the pharmaceutical industry now exceed $54 billion, and the three biggest retail chains alone have committed more than $13 billion to resolve state and local claims.¹²

Opioid Lawsuits Against CVS, Walgreens, and Walmart

Thousands of state and local governments, hospitals, and tribes sued the three largest pharmacy chains, alleging they failed to flag suspicious prescriptions and helped flood communities with pain pills. Most of those cases were consolidated into a single multidistrict litigation in the Northern District of Ohio, which remains active in 2026.³

In November 2021, a federal jury in Cleveland delivered the first jury verdict ever against retail pharmacies in an opioid case, finding that CVS, Walgreens, and Walmart had “substantially contributed to the crisis of opioid overdoses and deaths” in Lake and Trumbull counties, Ohio.⁴ Roughly 80 million prescription painkillers had been dispensed in Trumbull County alone between 2012 and 2016, about 400 per resident.⁵ The judge imposed a $650 million abatement plan.

That judgment did not last. On January 31, 2025, the Sixth Circuit vacated the entire $650 million order after the Ohio Supreme Court held that Ohio’s Product Liability Act bars common-law public nuisance claims arising from the sale of a product.⁶⁷ The only completed trial verdict against pharmacy chains was wiped out.

The chains scored a second defense win in 2026. Sixteen Florida hospitals had alleged the same chains violated the state’s anti-racketeering laws and stuck them with $528.3 million in direct opioid injury costs plus $1.5 billion in related treatment expenses. After a first trial ended in a mistrial, Broward County Chief Judge Carol-Lisa Phillips ruled for the pharmacies on May 26, 2026, finding the hospitals’ losses were only an indirect consequence of the chains’ conduct.⁸

The Nationwide Opioid Settlements

Even as trial results have gone against plaintiffs, the volume of litigation pushed every major chain to negotiate. In 2022, the three largest reached settlements with state and local governments totaling more than $13 billion:

Walgreens: up to $5.52 billion, paid over 15 years.
CVS: up to $4.90 billion, paid over 10 years.
Walmart: up to $2.74 billion, paid within six years.

The deals also require compliance structures covering pharmacist judgment, diversion prevention, suspicious order monitoring, and reporting on red-flag processes.²

Grocery-chain pharmacies followed. Kroger finalized a $1.37 billion nationwide settlement in November 2024, structured at roughly $140 million per year for the first six years and $110 million per year for the following five, and agreed to monitor and report suspicious opioid prescribing.⁹ Publix reached a settlement in July 2025 on undisclosed terms; a federal judge in Atlanta administratively closed the case pending finalization.¹⁰

At least 85% of the funds distributed under the national framework must go toward opioid abatement: prevention, harm reduction, treatment, and recovery.² Analysts have warned states against using the money to fill budget gaps or fund programs without an evidence base.¹

Federal DOJ Cases Against Pharmacy Chains

State and local settlements didn’t end federal exposure. The Department of Justice has pursued its own lawsuits under the Controlled Substances Act and the False Claims Act, focused on chains knowingly filling illegitimate prescriptions and billing government programs for them.

Walgreens: $350 Million

In January 2025, the DOJ intervened in four consolidated whistleblower cases alleging Walgreens knowingly filled millions of unlawful controlled substance prescriptions between roughly August 2012 and March 2023, with pharmacists pressured to fill quickly and ignore red flags.¹¹¹²¹³¹⁴ Walgreens has said the deal closes all opioid-related federal, state, and local litigation against it.

CVS: Pending

The DOJ filed a similar suit against CVS in December 2024 in the U.S. District Court for the District of Rhode Island, intervening in a whistleblower case first brought by former CVS pharmacist Hillary Estright in 2019. The government alleges CVS knowingly filled illegitimate opioid prescriptions from at least October 2013 onward, driven by corporate staffing policies and performance metrics that made compliance impossible, and that CVS declined to implement a due-diligence checklist for certain opioids to avoid roughly $11 million in labor costs.¹⁵ CVS has called the allegations a “false narrative,” arguing every disputed prescription involved an FDA-approved medication issued by a licensed practitioner, and says it will defend the case vigorously.¹⁶ The case remains pending, with no determination of liability.

Kroger: Under Investigation

In August 2025, the DOJ petitioned an Ohio federal court to force Kroger to produce unredacted patient records for a False Claims Act probe. The government alleges Kroger pharmacies billed Medicare and other programs for opioids that were “not reasonable, necessary, or eligible for coverage.” Kroger has partially complied but redacted patient data, citing breach liability; the DOJ says that refusal has no legal basis.¹⁷

CVS Insulin Pen Overbilling

Opioids aren’t the only False Claims Act exposure. In December 2025, CVS agreed to pay $37.76 million to resolve allegations that it overbilled government healthcare programs for insulin pens between 2010 and 2020 by dispensing more pens than prescribed, placing prescriptions on unauthorized automatic refill cycles, and underreporting days-of-supply to hide premature refills. CVS admitted responsibility. Five whistleblowers received about $7.1 million, or 19.5% of the recovery.¹⁸

The FTC Case Against Pharmacy Benefit Managers

The lawsuits reshaping what patients pay at the counter target the middle of the supply chain. In September 2024, the FTC sued the three largest pharmacy benefit managers — CVS Health’s Caremark Rx, Cigna’s Express Scripts, and UnitedHealth Group’s OptumRx — along with their affiliated group purchasing organizations. Together those three handle roughly 80% of all U.S. prescriptions. The FTC alleged they created a “perverse drug rebate system” that inflated insulin list prices by favoring high-cost, high-rebate products. The list price of Humalog, the agency noted, rose from $21 in 1999 to more than $274 by 2017.¹⁹

Express Scripts settled in February 2026, agreeing to base patient out-of-pocket costs on net prices rather than list prices, move its group purchasing organization from Switzerland to the United States, and reimburse retail pharmacies based on actual acquisition cost. The FTC projected the deal could save patients up to $7 billion in insulin costs over 10 years.²⁰ A similar deal with Caremark followed, with proceedings withdrawn in March 2026 for consideration of a consent agreement, and FTC staff signaled by May 2026 they were close to finalizing with OptumRx.²¹

States are pursuing their own PBM claims. Michigan filed an antitrust action against Express Scripts and Prime Therapeutics in May 2025, alleging an unlawful collaboration agreement used to suppress pharmacy reimbursement rates and harm independent pharmacies.²²

Rite Aid: Opioid Costs and a Data Breach

Rite Aid’s opioid exposure contributed to its bankruptcy, and the fallout is still in court. In October 2025, a Rite Aid bankruptcy trustee sued Walgreens in Delaware’s Chancery Court, alleging Walgreens is reneging on contractual obligations to cover opioid-related legal expenses for roughly 2,000 Rite Aid stores that Walgreens acquired. The trustee says Rite Aid spent tens of millions defending and settling more than 1,600 civil opioid cases that Walgreens agreed to reimburse.²³

Rite Aid also faced a class action over a June 2024 ransomware breach that exposed personal information for about 2.2 million customers, including names, addresses, dates of birth, and driver’s license numbers. The company reached a $6.8 million settlement in Bianucci v. Rite Aid Corporation, which received preliminary approval in March 2025 in the U.S. District Court for the Eastern District of Pennsylvania. Class members could claim up to $10,000 for documented losses or take a pro-rated cash payment, and Rite Aid agreed to cybersecurity improvements.²⁴

DEA Enforcement Against Independent Pharmacies

Independent pharmacies face their own enforcement risk, and the standards set in those cases shape how every pharmacist handles a controlled substance prescription. In January 2025, the DEA revoked the registration of Neumann’s Pharmacy in Tallulah, Louisiana, finding the pharmacist-in-charge repeatedly dispensed controlled substances despite obvious red flags: dangerous opioid-benzodiazepine combinations, therapeutic duplications, and cash payments used to avoid insurance monitoring. The agency emphasized that if efforts to resolve red flags aren’t documented at the time on the prescription, in the computer system, or in a logbook, it treats the investigation as not having happened.²⁵

The doctrine behind these cases is “corresponding responsibility,” established by the DEA in 1971, which requires pharmacists to independently verify that a controlled substance prescription serves a legitimate medical purpose before dispensing it. The specific red flags DEA investigators look for — cash payments, long travel distances, signs of doctor shopping — aren’t formally defined in any statute or regulation, leaving pharmacists to guess at the line.²⁶

Dispensing Errors and Patient Malpractice Claims

Away from the headline enforcement actions, pharmacies face a constant flow of private lawsuits from patients and families over dispensing errors: the wrong drug, the wrong dose, a missed interaction, an inadequate warning. A 2018 review of pharmacy malpractice claims found that “failure to identify overdosing” carried the highest average payout of any claim category at $544,600, and that overdose accounted for nearly 74% of pharmacy malpractice claims tied to patient deaths between 2012 and 2016.²⁷

Courts have held pharmacists liable even when they checked with the prescriber. In Brooks v. Wal-Mart Stores, Inc., a pharmacist called the doctor to verify an excessive prednisone dosage, filled it as written, and was held solely liable for the resulting harm in a $2.5 million judgment.²⁷ The duty to dispense safely exists independently of the prescriber’s judgment.

Individual pharmacists have also lost licenses and businesses. California regulators have revoked licenses in multiple cases involving pharmacists who ignored red flags on controlled substance prescriptions, including one owner whose license and business were both terminated after a board investigation into an overdose death linked to more than 4,500 controlled substance prescriptions filled without verification.²⁸ Legal experts have raised the possibility of criminal charges against individual pharmacists in future overdose cases.

1
RAND Corporation. Opioid Settlement Fund Allocation
2
National Opioid Settlement. Executive Summary
3
United States District Court, Northern District of Ohio. MDL 2804 National Prescription Opiate Litigation
4
The New York Times. Jury Holds Pharmacies Responsible for Role in Opioid Crisis
5
Fierce Healthcare. Federal Jury Holds CVS, Walgreens, and Walmart Responsible for Role in Opioid Crisis
6
Bloomberg Law. CVS, Walgreens, Walmart Evade $650 Million Ohio Opioid Judgment
7
U.S. Court of Appeals for the Sixth Circuit. In Re National Prescription Opiate Litigation, Nos. 22-3750 et al.
8
Reuters. CVS, Walgreens, Walmart Defeat Florida Hospitals Opioid Lawsuit
9
Colorado Attorney General. Finalize $1.37 Billion Nationwide Opioid Settlement With Kroger
10
The Ledger. Judge Orders Opioid Case Against Publix Closed Due to Settlement
11
U.S. Department of Justice. Justice Department Files Nationwide Lawsuit Alleging Walgreens Knowingly Filled Millions of Prescriptions That Lacked a Legitimate Medical Purpose
12
NPR. Walgreens Pay Opioid Settlement
13
U.S. Department of Justice. Walgreens Agrees to Pay $350M for Illegally Filling Unlawful Opioid Prescriptions
14
HHS Office of Inspector General. Walgreen Co. Corporate Integrity Agreement
15
U.S. Department of Justice. Justice Department Files Nationwide Lawsuit Alleging CVS Knowingly Dispensed Controlled Substances
16
Legal Dive. CVS Dispensed Opioid Drugs Unlawfully in Profit Push, US Suit Alleges
17
FOX19. Kroger Under Federal Investigation for Alleged False Medicare Opioid Claims
18
U.S. Department of Justice, Southern District of New York. US Attorney Announces $37.76 Million Settlement With CVS Over Dispensing Insulin Pens
19
Federal Trade Commission. FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices
20
Federal Trade Commission. Pharmacy Benefits Managers
21
Federal Trade Commission. In the Matter of Caremark Rx, Zinc Health Services, et al. (Insulin)
22
NPR. Insulin FTC Lawsuit Pharmacy Benefit Manager
23
Bloomberg Law. Walgreens Sued by Rite Aid Bankruptcy Trustee Over Opioid Costs
24
HIPAA Journal. Rite Aid Data Breach Settlement
25
Federal Register. Neumanns Pharmacy LLC Decision and Order
26
Drug Topics. Independent Pharmacies Must Be Prepared for DEA Inspections
27
National Library of Medicine. Pharmacy Malpractice Claims and Liability
28
Medscape. Pharmacist Liability for Opioid Overdose Deaths